# A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

> **NCT07383922** · PHASE3 · NOT_YET_RECRUITING · sponsor: **FutureGen Biopharmaceutical (Beijing) Co., Ltd** · enrollment: 524 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** FG-M108
- **DRUG:** nab paclitaxel
- **DRUG:** Gemcitabine (GEM)
- **DRUG:** Placebo for FG-M108

## Key facts

- **NCT ID:** NCT07383922
- **Lead sponsor:** FutureGen Biopharmaceutical (Beijing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 524 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07383922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07383922, "A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07383922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*